A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Diffuse Large B-cell Lymphoma
DRUG: SHR-A1912 Injection|DRUG: Rituximab Injection|DRUG: Gemcitabine Hydrochloride for Injection|DRUG: Oxaliplatin Injection
Complete response rate (CRR), Up to 1 years following the first dose of the last enrolled patient.|Overall survival (OS), Up to 5 years following the first dose of the last enrolled patient.
Adverse events (AEs), Up to 5 years following the first dose of the last enrolled patient.
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.